Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pemetrexed with Cisplatin or Carboplatin in NSCLC
NCT00269152Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2005
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Feasibility of Post-Surgery Chemotherapy. Started Dec 2005; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00269152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269152.